Compare SLAI & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
Current Price
Current Price
| Metric | SLAI | HOWL |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | 63 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 15.7M |
| IPO Year | N/A | 2021 |
| Metric | SLAI | HOWL |
|---|---|---|
| Price | $3.16 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 100.0K | ★ 993.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.27 |
| 52 Week High | $3.50 | $2.23 |
| Indicator | SLAI | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 81.51 | 39.65 |
| Support Level | $0.63 | $0.27 |
| Resistance Level | N/A | $0.76 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.27 | 0.01 |
| Stochastic Oscillator | 91.05 | 30.71 |
SOLAI Ltd is a technology-driven cryptocurrency infrastructure company. It is expanding from its foundation in crypto mining to build a blockchain-based ecosystem spanning AI, stablecoins, and payment infrastructure, and Solana treasury and staking operations supporting use cases across institutional settlement, commerce, consumer payments, and AI-native agent transactions. The group is leveraging its blockchain and data infrastructure expertise, aiming to enhance on-chain efficiency and expand participation across Solana and other blockchain ecosystems.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.